Daily Ards Research Analysis
Analyzed 7 papers and selected 3 impactful papers.
Summary
Three studies advance ARDS care from different angles: a large, multicentre randomized trial protocol testing individualized ventilator strategies; a retrospective pediatric cohort showing superior survival with noninvasive respiratory support versus invasive ventilation in scrub typhus-related respiratory failure; and a detailed case report suggesting that a short, carefully monitored corticosteroid course may aid aspiration-related ARDS recovery.
Research Themes
- Physiology-driven individualized ventilation strategies in ARDS
- Noninvasive respiratory support outcomes in pediatric infectious ARDS
- Targeted, time-limited corticosteroids in aspiration-related ARDS
Selected Articles
1. Careful ventilation in acute respiratory distress syndrome: the protocol of the CAVIARDS international multicentre randomised basket trial.
This international, investigator-initiated RCT will test a physiology-guided individualized ventilation strategy against conventional PEEP-FiO2 tables in moderate-to-severe ARDS, with 60-day all-cause mortality as the primary endpoint. The design includes assessment of lung recruitability and airway opening pressure, control of distending pressure, and respiratory drive, across COVID-19 and non-COVID-19 ARDS subgroups.
Impact: If positive, this trial could redefine ventilator management by operationalizing bedside physiology to tailor PEEP and pressure targets, potentially lowering mortality and ventilator-induced lung injury.
Clinical Implications: While results are pending, the protocol highlights practical methods (one-breath derecruitment, airway opening pressure) that can be piloted in physiologically focused ARDS management and inform protocolized care.
Key Findings
- Multicentre, open-label RCT (33 centres, 8 countries) plans to enroll 740 patients with moderate-to-severe ARDS.
- Intervention arm individualizes PEEP via one-breath derecruitment and airway opening pressure, and controls distending pressure and respiratory drive.
- Two ARDS subpopulations (COVID-19-induced and non-COVID-19) will be analyzed with 60-day all-cause mortality as the primary outcome.
Methodological Strengths
- Pre-registered, adequately powered randomized design with clearly defined primary and secondary outcomes.
- Physiology-based intervention leveraging bedside measurements (recruitability, airway opening pressure) to tailor settings.
Limitations
- Open-label design may introduce performance bias.
- As a protocol paper, no efficacy results are yet available; implementation complexity may vary across centres.
Future Directions: Completion of the trial and subgroup analyses will clarify which patients benefit most; integration with diaphragm-protective strategies and automated monitoring could be explored.
INTRODUCTION: Acute respiratory distress syndrome (ARDS) is a major public health problem, accounting for 23% of intubated patients and associated with high mortality rates. Although lifesaving, invasive mechanical ventilation can worsen lung injury when ventilator settings are poorly adjusted to lung physiology. We hypothesise that individualising ventilator settings via (1) the bedside assessment of lung recruitability using a one-breath derecruitment manoeuvre and measurement of airway opening pressure to set positive end-expiratory pressure (PEEP), (2) controlling the distending pressure and (3) controlling respiratory drive improves ARDS outcomes. METHODS AND ANALYSIS: The CAreful Ventilation In ARDS trial is an investigator-led multicentre (33 centres in eight countries), open-label, randomised controlled basket trial comparing two ventilation strategies in two subpopulations of moderate-to-severe ARDS: induced or not by COVID-19. A total of 740 patients will be randomised (370 in each substudy) in a 1:1 ratio to individualised ventilator settings or to using traditional PEEP to inspired fraction of oxygen tables for PEEP setting. Indications for proning and weaning strategies are similar in both arms. The primary outcome is all-cause mortality at day 60. Secondary outcomes include duration of mechanical ventilation, duration of intensive care unit (ICU) and hospital stay, organ dysfunction, barotrauma and mortality in ICU, at day 28 and in hospital. ETHICS AND DISSEMINATION: Ethics approval has been obtained for all participating centres: Unity Health Toronto Research Ethics Board (for three centres: St Michael's Hospital, Toronto General Hospital and Toronto Western Hospital); Comité de Ética de Investigación con Medicamentos del Hospital Universitari Vall d'Hebron; Comité de protection des personnes Ile de France III; Comité d'Ética de la Investigatción con Medicamentos de la Fundació de Gestió Sanitària del Hospital de la Santa Creu i Sant Pau; Comitato Etico-Fondazione Policlinico Gemelli; Comitato Etico di Area Vasta Emilia Centro; NYU Langone Health Institutional Review Board; Comité Ético Científico de Ciencias de la Salud; Il Comitato Etico Area 1 dell'Azienda Ospedaliero-Universitaria 'Ospedali Riuniti' di Foggia; HIGA 'Eva Perón' Comité de Bioética; Comité de Revisión Institucional del Hospital Británico Comité de Ética en Investigación; Complejo Médico Churruca-Visca Comité de Ética Biomédica; Comité de Ética SATI Comité de Ética en Investigación; Comité de Ética en Investigación del CEMIC; Comité de Ética SATI Comité de Ética en Investigación; Medical Research Ethics Committees United. Findings will be disseminated in peer review journals and conference presentations. TRIAL REGISTRATION NUMBER: NCT03963622.
2. Outcomes of noninvasive versus invasive respiratory support in pediatric scrub typhus-associated acute respiratory failure: a retrospective cohort study from South India.
Among 160 children with scrub typhus-related ARF, initial noninvasive support (HHHFNC and/or NIV) was associated with markedly higher survival than IMV (96.3% vs 38.7%). NIV failure occurred in 22.5% and carried high mortality; several clinical and laboratory variables predicted failure, supporting vigilant monitoring and timely escalation.
Impact: Provides rare comparative outcomes data for respiratory strategies in pediatric infectious ARDS, informing triage and escalation decisions in resource-limited settings.
Clinical Implications: Consider prioritizing NIRS (HHHFNC/NIV) as initial support in pediatric scrub typhus ARDS while closely monitoring for predictors of NIV failure to ensure timely intubation when needed.
Key Findings
- In 160 children, initial support was HHHFNC (28.8%), NIV (32.5%), or IMV (38.7%).
- Overall survival was higher with NIRS than IMV (96.3% vs 38.7%, P<.001).
- NIV failure rate was 22.5% and was associated with 66.7% mortality.
- Predictors of NIV failure included younger age, male sex, facial puffiness, hepatomegaly, thrombocytopenia, elevated lactate, and higher SOFA, PIM2, and VIS scores.
Methodological Strengths
- Clearly defined exposure within first 4 hours (NIRS vs IMV) and comprehensive outcome assessment.
- Identification of NIV failure predictors using clinical and laboratory variables.
Limitations
- Retrospective, single-centre design with potential indication and confounding biases.
- Non-random allocation; residual confounding likely despite analyses.
Future Directions: Prospective multicentre studies or pragmatic trials should validate NIRS-first strategies and refine risk scores for NIV failure in pediatric infectious ARDS.
Scrub typhus is an important cause of acute febrile illness in children that may progress to acute respiratory failure (ARF). However, evidence for noninvasive respiratory support (NIRS) in this setting is limited. The main objective of this study is to compare outcomes of NIRS versus invasive mechanical ventilation (IMV) in pediatric scrub typhus-related ARF and identify predictors of NIV failure. This study included children aged 28 days-15 years with confirmed scrub typhus and ARF who were admitted to the pediatric critical care unit of a tertiary center in South India. Patients were classified according to the type of respiratory support in the first 4 h (NIRS: heated humidified high-flow nasal cannula [HHHFNC] and/or noninvasive ventilation [NIV]; or IMV). Clinical and laboratory data and outcomes were analyzed. The predictors of NIV failure were evaluated in a subgroup of NIV recipients. Of the 160 children, 46 (28.8%) received HHHFNC, 52 (32.5%) NIV, and 62 (38.7%) IMV as initial support. Eighteen NIV patients (34.6%) required intubation and were analysed with the IMV group (IMV n=80, NIRS n=80). The overall survival was 67.5%, higher with NIRS than IMV (96.3% vs 38.7%, P<.001). NIV failure occurred in 22.5% of patients and was associated with a mortality rate of 66.7%. Younger age, male sex, facial puffiness, hepatomegaly, thrombocytopenia, elevated lactate levels, and higher SOFA, PIM2, and VIS scores predicted NIV failure (P<.05). The duration of respiratory support, ICU stay, and inotrope use were greater with IMV. NIRS is effective and is associated with better survival in children with scrub typhus ARDS. Vigilant monitoring and early escalation in high-risk patients may improve outcomes.
3. Short-term corticosteroid therapy in aspiration pneumonitis complicated by acute respiratory distress syndrome: A case report.
A postpartum patient with aspiration pneumonitis progressing to ARDS achieved rapid oxygenation and successful extubation after a 2-day methylprednisolone course alongside lung-protective ventilation. The case underscores considering a time-limited, closely monitored corticosteroid trial in selected chemical aspiration-related ARDS.
Impact: Addresses a common yet poorly guided scenario—aspiration-related ARDS—by detailing a pragmatic, short steroid strategy with objective physiologic response.
Clinical Implications: In moderate-to-severe chemical aspiration-related ARDS, clinicians may consider a short, carefully monitored corticosteroid trial within lung-protective ventilation bundles, with rapid reassessment and de-escalation.
Key Findings
- Aspiration pneumonitis rapidly evolved to ARDS with a PaO2/FiO2 of 78.4 and diffuse bilateral infiltrates.
- Methylprednisolone 1 mg/kg/day for 2 days was associated with rapid oxygenation improvement, extubation by day 5, and discharge by day 10.
- Early lung-protective ventilation, consideration of bronchoscopy, and antimicrobial stewardship were emphasized.
Methodological Strengths
- Detailed physiologic characterization including PaO2/FiO2 and imaging/bronchoscopy findings.
- Clear, time-limited steroid regimen with objective clinical milestones (extubation day, discharge day).
Limitations
- Single case without a control group; causality cannot be inferred.
- Concurrent therapies (ventilation strategy, antibiotics) confound attribution to steroids.
Future Directions: Prospective registries and randomized pilot studies should evaluate timing, dose, and duration of corticosteroids in aspiration-related ARDS and identify responders.
RATIONALE: Aspiration of gastric contents (Mendelson syndrome) can cause chemical pneumonitis and quickly progress to acute respiratory distress syndrome (ARDS). Evidence for corticosteroids in this setting is limited, and guidelines are unclear. We describe a postpartum case of aspiration pneumonitis evolving to ARDS that improved after a short course of methylprednisolone. PATIENT CONCERNS: A 27-year-old woman developed severe dyspnea, chest tightness, and hypoxemia after a cesarean section performed under general anesthesia. DIAGNOSES: On arrival at Cho Ray Hospital, she was tachypneic with bilateral crackles and a PaO2/FiO2 ratio of 78.4. Chest radiography showed diffuse bilateral infiltrates, and bronchoscopy revealed edematous, secretion-free airways, findings consistent with aspiration pneumonitis progressing to early ARDS. INTERVENTIONS: The patient was intubated, treated with lung-protective mechanical ventilation, broad-spectrum antibiotics, supportive care, and intravenous methylprednisolone at 1 mg/kg/day for 2 days. OUTCOMES: Oxygenation indices rose rapidly after steroid initiation, allowing stepwise ventilator weaning. She was extubated on day 5 and discharged on day 10 without respiratory symptoms, and postpartum recovery was uneventful. LESSONS: Mendelson syndrome can progress within hours to severe ARDS even in otherwise healthy postpartum patients. Early airway protection with lung-protective ventilation, consideration of early bronchoscopy when feasible, and stewardship-based empiric antibiotics with de-escalation are important. A carefully monitored, time-limited corticosteroid trial may be considered in selected cases of chemical aspiration-related moderate to severe ARDS, but treatment should be individualized with close reassessment.